Palisade Bio, Inc.
NCM: PALILive Quote
📈 ZcoreAI Score
Our AI model analyzes Palisade Bio, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get PALI Z-Score →About Palisade Bio, Inc.
Healthcare
Biotechnology
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.
📊 Fundamental Analysis
Palisade Bio, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -24.5%, which indicates that capital utilization is currently under pressure.
At a current price of $1.82, PALI currently sits at the 61st percentile of its 52-week range (Range: $0.53 - $2.64).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
🔴
Return on Equity
Weak
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$305.07M
Trailing P/E
--
Forward P/E
-6.78
Beta (5Y)
1.47
52W High
$2.64
52W Low
$0.53
Avg Volume
4.11M
Day High
Day Low